True Bearing Diagnostics, Inc Information

True Bearing Diagnostics is a molecular diagnostics company advancing a new standard for infection detection through host-response biology. Built on foundational research from the St. Laurent Institute and George Washington University, the company is focused on addressing one of healthcare’s most persistent and costly challenges: accurately identifying infection at the earliest point of care. Its lead program, TruNAV™, is an RNA-based, pathogen-agnostic blood test designed to detect and differentiate bacterial, viral, and biofilm infections from a single sample. By measuring the body’s immune response—specifically neutrophil activation—TruNAV provides clinicians with a clearer, earlier understanding of infection presence and magnitude, even in cases where traditional diagnostics fall short or are inconclusive. True Bearing Diagnostics is advancing toward FDA clearance through multi-center clinical studies with leading institutions including UVA Health, Children’s National Hospital, and others. The initial indication is abdominal infection—representing over 16 million emergency department visits annually in the U.S.—with expansion potential across emergency medicine, infectious disease, and broader acute care settings. Designed for deployment on widely available digital PCR platforms, TruNAV enables scalable integration into existing laboratory infrastructure with the potential for rapid turnaround times post-clearance. By improving diagnostic accuracy at the front end of care, the platform aims to reduce unnecessary imaging and procedures, support antibiotic stewardship, and lower overall healthcare costs. True Bearing Diagnostics is positioned to define a new category in infection diagnostics—bringing precision, speed, and confidence to clinical decision-making while addressing a multibillion-dollar global market.